MBCproject_0227_T1_RNA
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.490
- MYC_TARGETS_V2+0.480
- G2M_CHECKPOINT+0.400
- DNA_REPAIR+0.300
- MYC_TARGETS_V1+0.270
- SPERMATOGENESIS+0.240
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.150
- OXIDATIVE_PHOSPHORYLATION+0.120
- ESTROGEN_RESPONSE_EARLY+0.100
- ESTROGEN_RESPONSE_LATE+0.100
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.510
- ALLOGRAFT_REJECTION-0.500
- IL6_JAK_STAT3_SIGNALING-0.480
- COMPLEMENT-0.430
- INFLAMMATORY_RESPONSE-0.430
- INTERFERON_GAMMA_RESPONSE-0.370
- HEDGEHOG_SIGNALING-0.350
- KRAS_SIGNALING_UP-0.350
- P53_PATHWAY-0.320
- UV_RESPONSE_DN-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_R439VVPK | medulloblastoma | — | 0.887 |
| 2 | BS_HE57E1RP | medulloblastoma | — | 0.883 |
| 3 | TCGA-44-7667-01A-31R-2066-07 | — | cohortA3 | 0.866 |
| 4 | BS_9NZ2D6AD | medulloblastoma | — | 0.861 |
| 5 | SRR6013537 | — | cohortA3 | 0.859 |
| 6 | BSR_04_0040_A3_S71 | — | B | 0.858 |
| 7 | BS_FKDQJJB5 | medulloblastoma | — | 0.857 |
| 8 | C3L-01285 | — | cohortSQ2 | 0.855 |
| 9 | BS_81SP2HX4 | medulloblastoma | — | 0.853 |
| 10 | TCGA-E9-A2JS-01A-11R-A180-07 | — | B | 0.853 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.490 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.480 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.270 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.240 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.150 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.120 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.100 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.060 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.020 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.020 | Idelalisib | — uncovered |